RE:Global Joint Venture or PartnershipCZO October 2022 news release:
Knowing that Ceapro’s PGX-processed carriers can deliver CoQ10 into the tissues, we will advance to the next stage which includes looking for efficacy of these new chemical entities along with a partner involved in the marketing and sales of various forms of delivery systems that can be included in food, drinks, cream formulations, medical supplies like thin films, skin patches and up to nutraceuticals and pharmaceuticals,” said Gilles Gagnon, M.Sc., MBA, President and CEO.
------
Biotech happens in slow motion but since that CoQ10 bioavailability data in October 2022 at the AGM Gilles said they were in talks with serious potential partners who understand bioavailability as a unique selling point. CZO has completed the merger with AEZS to optimize its resources/structure. The 50L PGX facility has been commissioned and is being fine tuned and the first PGX product could be approved within about six months. The 50L facility was to provide materials for potential partners. We may now be three months from commissioning the decision point for mass industrialization(100L).